PATENT CLAIM ANALYSIS

Application Number: 16228284
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["544", "376000"]

Abstract:
The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

Claim (Index 7):
The heterocyclic compound of the formula (1) according to  claim 3  selected from the group consisting of:\n (1) 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one, \n (2) 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl) propoxy]-1H-quinolin-2-one, \n (3) 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl) propoxy]-3,4-dihydro-1H-quinolin-2-one, \n (4) 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl) butoxy]-3,4-dihydro-1H-quinolin-2-one, \n (5) 7-[4-(4-benzo[b]thiophen-4-yL-piperazin-1-yl) butoxy]-1-methyl-3,4-dihydro-1H-quino 1 in-2-one and \n (6) 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl) propoxy]-3,4-dihydro-1H-quinolin-2-one; \n or a salt thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 98.0
- Lexical Diversity: 1.19444
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15697196', '12970690', '14089504', '11659005', '14928972']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8590454512973075
- 35 USC 102 Novelty (BERT): 0.6277170960234477
- Combined Prediction Score: 0.8359126157699215
- Mean Citation Score: 556.557896
- Max Citation Score: 585.1553299999998
- Similarity Product: 575.091220389552

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test